FDA 2022 Rewind: GI drug pipeline rattles as FDA delivers 7 new drugs, 1 costly rejection

Gastroenterology had a big year in 2022, with potentially game-changing FDA approvals for inflammatory bowel disease and several first-in-class therapies, yet the FDA’s rejection of the first hepatitis D therapy still looms large.Over the past year, the FDA has greenlit several notable additions to the gastroenterology armamentarium, including the first treatment for eosinophilic esophagitis and the first approved fecal microbiota therapeutic, as well as well new gastrointestinal indications for two blockbuster biologics.Healio has closely followed these FDA decisions throughout theRead More